Aaron Royston, M.D., M.B.A. is a Managing Partner at venBio. He has more than 15 years of experience in life sciences investing, company formation and operations, strategic and product planning in the biotechnology industry, and clinical research.
He has helped to launch, invest, and serve on the board of a number of venBio companies including Apellis Pharmaceuticals (IPO 2017), Menlo Therapeutics (IPO 2018), Akero Therapeutics (IPO 2019), Harmony Biosciences (IPO 2020), Ventyx BioSciences (IPO 2021), RayzeBio (IPO 2023, acquired by BMS), Ablaze Pharmaceuticals, 35Pharma, Attovia Therapeutics, and ViceBio. These companies’ efforts have led to six FDA drug approvals.
1700 Owens Street, Suite 595
San Francisco, CA 94158
1200 Westlake Ave N, Suite 900
Seattle, WA 98109
© 2024 venBio. All Rights Reserved.